The FDA has granted a priority review designation to a supplemental biologics license application for nivolumab (Opdivo) plus ipilimumab (Yervoy) in previously untreated patients with advanced melanoma, according to a statement from the regimen’s developer, Bristol-Myers Squibb.
Publications
Nivolumab in the treatment of malignant melanoma: Review of the literature
Nivolumab (Opdivo) can become an alternative therapy for advanced malignant melanoma, according to a literature review published in the journal OncoTargets and Therapy.
Metastatic Melanoma Responsive To IL-2, Imiquimod Combo
A combination therapy of intralesional interleukin (IL)-2 administered with topical imiquimod and a retinoid cream resulted in complete local response in 100% of 11 patients with metastatic melanoma, a small retrospective case study has revealed (J Am Acad Dermatol2015;73[4]:645-654, PMID: 26259990).
Aura Biosciences Announces Publication Describing Selective Binding of Viral-like Particles to Cancer Cells
CAMBRIDGE, Mass – Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells, announced today the publication of a new paper demonstrating how its synthetic Viral-like Particles (VLP) modeled on the human papillomavirus (HPV) are able to bind uniquely to cancer cells while leaving healthy surrounding tissue unharmed.